MCID: PLY011
MIFTS: 65

Polycystic Ovary Syndrome

Categories: Rare diseases, Endocrine diseases

Aliases & Classifications for Polycystic Ovary Syndrome

MalaCards integrated aliases for Polycystic Ovary Syndrome:

Name: Polycystic Ovary Syndrome 37 12 24 36 51 40 41 14 69
Polycystic Ovarian Syndrome 72 49 24
Polycystic Ovaries 12 28 51
Pcos 12 49 24
Polycystic Ovarian Disease 12 24
Stein-Leventhal Syndrome 12 24
Sclerocystic Ovaries 24 69
Multicystic Ovaries 12 24
Sclerocystic Ovarian Degeneration 24
Sclerocystic Ovary Syndrome 24
Cystic Disease of Ovaries 24
Cystic Disease of Ovary 24
Stein-Leventhal Synd. 12
Polycystic Ovary 12
Pcod 24
Pco 24

Classifications:



External Ids:

Disease Ontology 12 DOID:11612
ICD10 32 E28.2
ICD9CM 34 256.4
MeSH 41 D011085
NCIt 46 C26862
KEGG 36 H01739

Summaries for Polycystic Ovary Syndrome

MedlinePlus : 40 Polycystic ovary syndrome (PCOS) happens when a woman's ovaries or adrenal glands produce more male hormones than normal. PCOS causes cysts (fluid-filled sacs) to grow on the ovaries. Symptoms include Irregular menstrual periods Infertility Pelvic pain Excess hair growth on the face, chest, stomach, or thighs Weight gain Acne or oily skin Patches of thickened skin Women with PCOS are at higher risk of diabetes, metabolic syndrome, heart disease, and high blood pressure. PCOS is more common in women who have obesity, or have a mother or sister with PCOS. To diagnose PCOS, your health care provider may do a physical exam, pelvic exam, blood tests, and an ultrasound. There is no cure, but diet, exercise, and medicines can help control the symptoms. Birth control pills help women have normal periods, reduce male hormone levels, and clear acne. Treatments for infertility caused by PCOS may include medicines, surgery, and in vitro fertilization (IVF). NIH: National Institute of Child Health and Human Development

MalaCards based summary : Polycystic Ovary Syndrome, also known as polycystic ovarian syndrome, is related to aromatase deficiency and acanthosis nigricans, and has symptoms including pelvic pain An important gene associated with Polycystic Ovary Syndrome is PCOS1 (Polycystic Ovary Syndrome 1), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Prolactin Signaling Pathway. The drugs Metformin and Cyproterone Acetate have been mentioned in the context of this disorder. Affiliated tissues include ovary, heart and skin, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : 12 A syndrome characterized by hyperandrogenism, polycystic ovaries, hirsutism, oligomenorrhea or amenorrhea, anovulation and excessive body weight.

Genetics Home Reference : 24 Polycystic ovary syndrome is a condition that affects women in their child-bearing years and alters the levels of multiple hormones, resulting in problems affecting many body systems.

NIH Rare Diseases : 49 Polycystic ovarian syndrome (PCOS) is a health problem that can affect a woman's menstrual cycle, ability to have children, hormones, heart, blood vessels, and appearance. Women with this condition typically have high levels of  hormones called androgens, missed or irregular periods, and many small cysts in their ovaries. The cause of PCOS is unknown, but probably involves a combination of genetic and environmental factors. Treatment for PCOS may involve birth control pills and medications for diabetes and infertility. Medicines called anti-androgens are also used to speed the growth of hair and clear acne. Last updated: 6/7/2016

Related Diseases for Polycystic Ovary Syndrome

Diseases in the Polycystic Ovary Syndrome family:

Polycystic Ovary Syndrome 1

Diseases related to Polycystic Ovary Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 225)
# Related Disease Score Top Affiliating Genes
1 aromatase deficiency 32.7 CYP19A1 GNRH1 INS
2 acanthosis nigricans 31.0 INS INSR LEP SHBG
3 infertility 30.9 CYP19A1 FSHR GNRH1 PRL
4 hyperprolactinemia 30.7 GNRH1 IGF1 PRL
5 sleep apnea 30.7 IGF1 INS LEP
6 central precocious puberty 30.6 GNRH1 IGF1 LEP
7 androgenic alopecia 30.6 CYP19A1 PRL SHBG
8 glucose intolerance 30.5 IGF1 IGFBP1 INS INSR LEP SHBG
9 gestational diabetes 30.5 CAPN10 INS INSR LEP SHBG
10 hyperglycemia 30.5 IGF1 INS INSR LEP
11 ovarian hyperstimulation syndrome 30.5 CYP19A1 FSHR GNRH1
12 breast disease 30.5 IGF1 PRL SHBG
13 amenorrhea 30.4 FSHR GNRH1 LEP PRL SHBG
14 ovarian disease 30.4 CYP11A1 CYP19A1 FSHR GDF9 GNRH1 IGF1
15 diabetes mellitus 30.4 CAPN10 IGF1 INS INSR LEP SHBG
16 hyperinsulinism 30.4 IGF1 IGFBP1 INS INSR LEP SHBG
17 hyperandrogenism 30.3 CYP17A1 CYP19A1 CYP21A2 GNRH1 HSD3B2 IGF1
18 precocious puberty 30.2 CYP19A1 CYP21A2 GNRH1
19 insulin-like growth factor i 30.2 IGF1 IGFBP1 INS INSR LEP PRL
20 estrogen excess 30.2 CYP19A1 FSHR SHBG
21 myoma 30.1 CYP19A1 GNRH1 LEP
22 anovulation 30.1 CYP19A1 FSHR GNRH1 IGF1 INS LEP
23 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 30.0 CYP21A2 LEP
24 transsexualism 30.0 CYP17A1 CYP19A1 CYP21A2
25 acromegaly 29.9 IGF1 IGFBP1 INS PRL
26 cortisone reductase deficiency 29.9 CYP21A2 H6PD HSD11B1
27 3-beta-hydroxysteroid dehydrogenase deficiency 29.9 CYP21A2 HSD3B2
28 body mass index quantitative trait locus 11 29.7 CAPN10 CYP21A2 H6PD HSD11B1 IGF1 IGFBP1
29 endometrial cancer 29.5 CYP19A1 GNRH1 IGF1 IGFBP1 INS SHBG
30 premature ovarian failure 1 29.5 CYP11A1 CYP19A1 FSHR GDF9 GNRH1 PRL
31 lipoid congenital adrenal hyperplasia 29.3 CYP11A1 CYP17A1 CYP21A2 HSD3B2
32 polycystic ovary syndrome 1 12.3
33 cortisone reductase deficiency 1 11.4
34 acth-independent macronodular adrenal hyperplasia 11.0
35 ovarian cyst 11.0
36 hair-an syndrome 11.0
37 body mass index quantitative trait locus 9 10.9
38 body mass index quantitative trait locus 8 10.9
39 body mass index quantitative trait locus 7 10.9
40 body mass index quantitative trait locus 12 10.9
41 body mass index quantitative trait locus 14 10.9
42 body mass index quantitative trait locus 18 10.9
43 body mass index quantitative trait locus 4 10.9
44 body mass index quantitative trait locus 10 10.9
45 insulin autoimmune syndrome 10.7 INS INSR
46 hyperandrogenism due to cortisone reductase deficiency 10.6 H6PD HSD11B1
47 secondary adrenal insufficiency 10.6 IGF1 INS
48 abdominal obesity-metabolic syndrome 1 10.6 HSD11B1 INS LEP
49 hypoactive sexual desire disorder 10.6 CYP19A1 SHBG
50 galactorrhea 10.6 IGF1 PRL

Graphical network of the top 20 diseases related to Polycystic Ovary Syndrome:



Diseases related to Polycystic Ovary Syndrome

Symptoms & Phenotypes for Polycystic Ovary Syndrome

UMLS symptoms related to Polycystic Ovary Syndrome:


pelvic pain

GenomeRNAi Phenotypes related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

25 (show all 23)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.78 IGF1 LEP
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-112 9.78 LEP
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.78 IGF1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.78 CYP21A2 IGF1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-142 9.78 INSR
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-144 9.78 IGF1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.78 CYP21A2
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.78 IGF1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 9.78 INSR
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-184 9.78 CYP21A2
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 9.78 SHBG
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 9.78 IGF1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.78 IGF1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 9.78 CYP21A2
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-206 9.78 CYP21A2
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.78 SHBG CYP21A2 IGF1 INSR LEP
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.78 LEP
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.78 IGF1
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.78 INSR
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.78 LEP
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.78 INSR
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.78 INSR
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 9.78 IGF1

MGI Mouse Phenotypes related to Polycystic Ovary Syndrome:

43 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.32 GNRH1 H6PD INS HSD11B1 INSR IGF1
2 homeostasis/metabolism MP:0005376 10.31 GNRH1 H6PD INS HSD11B1 IGF1 GDF9
3 growth/size/body region MP:0005378 10.27 IGF1 GNRH1 H6PD INS HSD11B1 CYP19A1
4 cellular MP:0005384 10.24 IGF1 IGFBP1 INS HSD11B1 FST CYP19A1
5 cardiovascular system MP:0005385 10.21 IGF1 INS HSD11B1 CYP19A1 CAPN10 CYP11A1
6 adipose tissue MP:0005375 10.18 INS HSD11B1 IGF1 CYP19A1 CAPN10 FSHR
7 immune system MP:0005387 10.18 IGF1 GNRH1 IGFBP1 INS HSD11B1 CYP19A1
8 integument MP:0010771 10.02 IGF1 GNRH1 INS HSD11B1 CYP19A1 FSHR
9 liver/biliary system MP:0005370 10.02 GNRH1 IGFBP1 INS HSD11B1 CYP19A1 CAPN10
10 muscle MP:0005369 9.91 IGF1 H6PD INS HSD11B1 CYP19A1 CYP11A1
11 nervous system MP:0003631 9.9 IGF1 GNRH1 INS HSD11B1 FST CYP19A1
12 renal/urinary system MP:0005367 9.56 IGF1 GNRH1 INS CYP19A1 CAPN10 CYP17A1
13 reproductive system MP:0005389 9.4 GNRH1 INS IGF1 GDF9 CYP11A1 FSHR

Drugs & Therapeutics for Polycystic Ovary Syndrome

Drugs for Polycystic Ovary Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 345)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 657-24-9 4091 14219
2
Cyproterone Acetate Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1 427-51-0
3
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-28-2 5757
4
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 57-63-6 5991
5
Orlistat Approved, Investigational Phase 4,Phase 2 96829-58-2 3034010
6
Ganirelix Approved Phase 4,Early Phase 1 124904-93-4, 123246-29-7 25081094
7
Drospirenone Approved Phase 4,Phase 3,Phase 1 67392-87-4 68873
8
Hydrocortisone Approved, Vet_approved Phase 4,Early Phase 1 50-23-7 657311 5754
9
Pioglitazone Approved, Investigational Phase 4,Early Phase 1 111025-46-8 4829
10
Simvastatin Approved Phase 4,Phase 3 79902-63-9 54454
11
Menotropins Approved Phase 4,Phase 2,Phase 1 9002-68-0, 61489-71-2 5360545
12
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Early Phase 1 57-83-0 5994
13
Zinc Approved, Investigational Phase 4,Early Phase 1 7440-66-6 32051 23994
14
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112809-51-5 3902
15
Resveratrol Approved, Experimental, Investigational Phase 4,Phase 3,Phase 1 501-36-0 445154
16
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-22-0 6013
17
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 1 71-58-9
18
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
19
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 3 616-91-1 12035
20
Liraglutide Approved Phase 4 204656-20-2 44147092
21
Citalopram Approved Phase 4 59729-33-8 2771
22
Epinephrine Approved, Vet_approved Phase 4,Early Phase 1 51-43-4 5816
23 Racepinephrine Approved Phase 4,Early Phase 1 329-65-7
24
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
25
Leuprolide Approved, Investigational Phase 4,Phase 2,Early Phase 1 53714-56-0 657181 3911
26
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
27
Hydroxocobalamin Approved Phase 4 13422-51-0 5460373 44475014 11953898
28
Alogliptin Approved Phase 4 850649-61-5 11450633
29
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
30
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
31
Tamoxifen Approved Phase 4 10540-29-1 2733526
32
Exenatide Approved, Investigational Phase 4,Phase 3,Phase 2 141758-74-9 15991534
33
Desogestrel Approved Phase 4,Phase 3 54024-22-5 40973
34
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
35
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
36
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 77-92-9 311
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 59-30-3 6037
38
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 58-05-9 143 6006
39
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 67-97-0 10883523 5280795 6221
40
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 50-14-6 5280793
41
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 1406-16-2
42
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
43
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
44
Nicotinamide Approved, Investigational, Nutraceutical Phase 4 98-92-0 936
45
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
46
Manganese Approved, Nutraceutical Phase 4 7439-96-5 27854
47
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 4 13422-55-4
48
Inulin Approved, Investigational, Nutraceutical Phase 4 9005-80-5 24763
49
Enclomiphene Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15690-57-0
50
2,4-thiazolidinedione Investigational Phase 4,Early Phase 1 2295-31-0

Interventional clinical trials:

(show top 50) (show all 554)

# Name Status NCT ID Phase Drugs
1 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4 Metformin
2 the Effect of Diane-35 Pretreatment on In-vitro Fertilization Outcome for Patients With Polycystic Ovary Syndrome Unknown status NCT01752270 Phase 4 Diane-35 pretreatment;Diane-35 pretreatment
3 The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT01475019 Phase 4 Orlistat;Sibutramine
4 Surgical Ovarian Drilling Versus Hormonal Treatment for Infertility Associated to PolyCystic Ovaries Syndrome (PCOS) Unknown status NCT00378729 Phase 4 Metformin and FSHr
5 Strategies for Ovulation Induction in Anovulatory Infertile Patients With PCOS Unknown status NCT00461643 Phase 4 Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins
6 Metformin in Infertile PCOS Patients Unknown status NCT00501904 Phase 4 Metformin
7 Endometrial Scratching During Laproscopic Ovarian Drilling in Subfertile PCOS Women Unknown status NCT02140398 Phase 4
8 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
9 PCOS, Therapy and Markers of Cardiovascular Risk Unknown status NCT01798875 Phase 4 oral metformin;oral contraceptive
10 Metformin in Step-down Regimen Versus Conventional Low Dose Step-up Protocol in Patients With PCOS Undergoing IVF Unknown status NCT01438190 Phase 4 Metformin, gonadotropins in step-down regimen;Placebo, gonadotropins in step-up regimen
11 Metformin and Gestational Diabetes in High-risk Patients: a RCTs Unknown status NCT00883259 Phase 4 Metformin
12 Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients Unknown status NCT00417144 Phase 4 Arvekap 0.1mg (Triptorelin, Ipsen, France);Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)
13 Adding L-carnitine in Clomiphene Resistant Polycystic Ovary Improves the Quality of Ovulation and the Pregnancy Outcome Unknown status NCT01665547 Phase 4 l-carnitine
14 Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants Unknown status NCT02027337 Phase 4 20 mcg ethinylestradiol /3 mg drospirenone;20 mcg ethinylestradiol/3 mg drospirenone and Selmevit;30 mcg ethinylestradiol/3 mg drospirenone;30 mcg ethinylestradiol/3 mg drospirenone and Selmevit;35 mcg ethinylestradiol/2 mg cyproterone;35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
15 Corifollitropin Alfa Application in PCOS Patients Unknown status NCT02215135 Phase 4 Corifollitropin alfa
16 Metformin for the Treatment of Unexplained Oligozspermia Unknown status NCT01529177 Phase 4 Metformin / clomid / hCG;Clomiphene citrate / hCG
17 Efficacy of Corifollitropin Alfa in Obese Women in Terms of Clinical and Molecular Parameters of IVF Success Unknown status NCT02606500 Phase 4 Elonva
18 Polycystic Ovary Syndrome - Improving Outcomes Completed NCT01504321 Phase 4 Moxonidine;Placebo
19 N-acetyl Cysteine for Ovulation Induction in Clomiphene Citrate Resistant Polycystic Ovary Syndrome Completed NCT02239107 Phase 4 N-Acetyl cysteine
20 Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome Completed NCT00679679 Phase 4 Metformin;Placebo
21 Trial With Metformin in Women With Polycystic Ovary Syndrome Completed NCT02280057 Phase 4 Metformin;Placebo
22 PCOSMIC Trial - PolyCystic Ovary Syndrome, Metformin for Infertility With Clomiphene Completed NCT00795808 Phase 4 Metformin;Placebo;Metformin + Clomiphene;Metformin;Clomiphene
23 Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome Completed NCT01118598 Phase 4 tredaptive (nicotinic acid/ laropiprant);placebo
24 The Effects of Fish Oils on Blood Pressure, Heart Rate Variability and Liver Fat in the Polycystic Ovary Syndrome Completed NCT00620529 Phase 4
25 Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism Completed NCT01360996 Phase 4 3 mg DRSP/20 μg EE
26 LIPT - Liraglutide in Polycystic Ovary Syndrome Completed NCT02073929 Phase 4 Liraglutide;placebo
27 The Effects of Vitamin D on Transforming Growth Factor-beta1 in Polycystic Ovary Syndrome Completed NCT02460380 Phase 4 Vitamin D3
28 The Effect of Ethinyl Estradiol on Polycystic Ovary Syndrome Women Undergoing Intrauterine Insemination Completed NCT01219101 Phase 4 clomiphene citrate with ethinyl esteradiol;clomiphene citrate with plasebo
29 Metformin and Folate Supplementation in Polycystic Ovary Syndrome (PCOS) Patients Completed NCT00953355 Phase 4 Folate plus metformin;Placebo plus metformin
30 Short-term Structured Exercise Training Program Plus Diet Intervention in Patients With Polycystic Ovary Syndrome (PCOS) Completed NCT01004068 Phase 4 Clomiphene citrate
31 Pioglitazone Treatment in Polycystic Ovary Syndrome Completed NCT00145340 Phase 4 pioglitazone
32 Polycystic Ovary Syndrome and Liraglutide Completed NCT01899430 Phase 4 liraglutide;metformin
33 Metformin and Folate in Pregnant Polycystic Ovary Syndrome(PCOS) Women Completed NCT01115140 Phase 4 metformin plus placebo;Metformin plus folic acid;placebo plus folic acid;placebo alone
34 Study of Mechanisms of Anovulation in Polycystic Ovary Syndrome Completed NCT00492882 Phase 4 usual administration of exogenous recombinant FSH
35 The Effect of Cipralex on Quality of Life, Adrenal Activity Glucose Metabolism, Physical and Mental Health in PCOS Completed NCT01961180 Phase 4 Cipralex;Placebo
36 Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study Completed NCT01021579 Phase 4 Metformin plus Placebo;Metfomin plus Simvastatin
37 Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin Completed NCT01911468 Phase 4 metformin;liraglutide;metformin and liraglutide
38 PDE-4 Inhibitor Roflumilast and Polycystic Ovary Syndrome Completed NCT02037672 Phase 4 metformin;metformin and roflumilast
39 PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome Completed NCT02187250 Phase 4 metformin;liraglutide;roflumilast
40 Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study Completed NCT00640224 Phase 4 rosiglitazone;drospirenone/ethinyl estradiol
41 Effects of Metformin vs Oral Contraceptives on CV Risk Markers in PCOS Completed NCT00428311 Phase 4 Metformin;Ethynyl-estradiol plus cyproterone acetate
42 Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS) Completed NCT00805935 Phase 4 Menotropin;Progesterone vaginal insert;Follitropin beta;Progesterone in oil;leuprolide acetate
43 Metformin in High Responder Polycystic Ovary Syndrome (PCOS) Patients Undergoing IVF Cycles Completed NCT01233206 Phase 4 Metformin;Placebo administration
44 Metformin Suspension and Insulin Sensitivity Completed NCT00437333 Phase 4 Metformin cloridrate
45 Ovarian Stimulation and Intrauterine Insemination in Women With Polycystic Ovarian Syndrome Completed NCT01675843 Phase 4
46 Role of Melatonin Supplementation in Follicular Fluid of in Vitro Fertilization (IVF) Patients With Polycystic Ovarian Syndrome Completed NCT01540747 Phase 4
47 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4 Drospirenone Ethinyl estradiol;Drospirenone Ethinyl estradiol Myo-inositol;placebo
48 Epicardial Adipose Tissue Thickness in Polycystic Ovary Syndrome (PCOS) Completed NCT01258946 Phase 4
49 Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome Completed NCT03122041 Phase 4 Sitagliptin
50 Metformin and Oral Contraceptives in PCOS Completed NCT00451568 Phase 4 Metformin;Desorelle

Search NIH Clinical Center for Polycystic Ovary Syndrome

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: polycystic ovary syndrome

Genetic Tests for Polycystic Ovary Syndrome

Genetic tests related to Polycystic Ovary Syndrome:

# Genetic test Affiliating Genes
1 Polycystic Ovaries 28

Anatomical Context for Polycystic Ovary Syndrome

MalaCards organs/tissues related to Polycystic Ovary Syndrome:

38
Ovary, Heart, Skin, Liver, Testes, Endothelial, Pituitary

Publications for Polycystic Ovary Syndrome

Articles related to Polycystic Ovary Syndrome:

(show top 50) (show all 2418)
# Title Authors Year
1
Non-targeted profiling of circulating microRNAs in women with polycystic ovary syndrome (PCOS): effects of obesity and sex hormones. ( 29410349 )
2018
2
Metformin and pioglitazone combination therapy ameliorate polycystic ovary syndrome through AMPK/PI3K/JNK pathway. ( 29434814 )
2018
3
Wilms' Tumor 1 Overexpression in Granulosa Cells Is Associated with Polycystic Ovaries in Polycystic Ovary Syndrome Patients. ( 29414825 )
2018
4
Association between Th1/Th2 immune imbalance and obesity in women with or without polycystic ovary syndrome. ( 29447491 )
2018
5
Enlarged adipocytes in subcutaneous adipose tissue associated to hyperandrogenism and visceral adipose tissue volume in women with polycystic ovary syndrome. ( 29273198 )
2018
6
The Role of C-Peptide as Marker of Cardiometabolic Risk in Women With Polycystic Ovary Syndrome: A Controlled Study. ( 29416587 )
2018
7
The numbers of 2- 5 and 6-9 mm ovarian follicles are inversely correlated in both normal women and in polycystic ovary syndrome patients: what is the missing link? ( 29425289 )
2018
8
High-molecular-weight adiponectin is inversely associated with sympathetic activity in polycystic ovary syndrome. ( 29428305 )
2018
9
Elevated CD14<sup>++</sup>CD16<sup>+</sup>Monocytes in Hyperhomocysteinemia-Associated Insulin Resistance in Polycystic Ovary Syndrome. ( 29439619 )
2018
10
Polycystic ovary syndrome in mitochondrial disorders due mtDNA or nDNA variants. ( 29422990 )
2018
11
Lipidomics reveals altered biosynthetic pathways of glycerophospholipids and cell signaling as biomarkers of the polycystic ovary syndrome. ( 29435121 )
2018
12
Sleep disturbances in women with polycystic ovary syndrome: prevalence, pathophysiology, impact and management strategies. ( 29440941 )
2018
13
Re: Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. ( 29210151 )
2018
14
Reproductive and metabolic determinants of granulosa cell dysfunction in normal-weight women with polycystic ovary syndrome. ( 29428312 )
2018
15
Aerobic Training Improves Quality of Life in Women with Polycystic Ovary Syndrome. ( 29443823 )
2018
16
Improvement of hyperandrogenism, oligo-ovulation, and ovarian morphology in a patient with polycystic ovary syndrome: possible role of ovarian wedge resection. ( 29298536 )
2018
17
Differential rate in decline in ovarian reserve markers in women with polycystic ovary syndrome compared with control subjects: results of a longitudinal study. ( 29428308 )
2018
18
Limitations of insulin resistance assessment in polycystic ovary syndrome. ( 29436386 )
2018
19
Infertile polycystic ovary syndrome patients undergoing in vitro fertilization with the gonadotropin-releasing hormone-antagonist protocol: role of hyperandrogenism. ( 29376451 )
2018
20
Correction to: Seyyed Abootorabi et al., The effect of vitamin D supplementation on insulin resistance, visceral fat and adiponectin in vitamin D deficient women with polycystic ovary syndrome: a randomized placebo-controlled trial. ( 29447022 )
2018
21
Heterogenous origins of hyperandrogenism in the polycystic ovary syndrome in relation to body mass index and insulin resistance. ( 29068242 )
2018
22
Polymorphisms in the TFAM and PGC1-I+ genes and their association with polycystic ovary syndrome among South Indian women. ( 29030253 )
2018
23
Impact of cancer treatment on risk of infertility and diminished ovarian reserve in women with polycystic ovary syndrome. ( 29428311 )
2018
24
The preliminary association study of ADIPOQ, RBP4, and BCMO1 variants with polycystic ovary syndrome and with biochemical characteristics in a cohort of Polish women. ( 29428584 )
2018
25
Authors' reply re: Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. ( 29226510 )
2018
26
Hidradenitis suppurativa is associated with polycystic ovary syndrome: a population-based analysis in the United States. ( 29378201 )
2018
27
Gut Microbial Diversity in Women with Polycystic Ovary Syndrome Correlates with Hyperandrogenism. ( 29370410 )
2018
28
Age-stratified thresholds of anti-MA1llerian hormone improve prediction of polycystic ovary syndrome over a population-based threshold. ( 28949024 )
2017
29
Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease. ( 28370150 )
2017
30
Androsterone glucuronide to dehydroepiandrosterone sulphate ratio is discriminatory for obese Caucasian women with polycystic ovary syndrome. ( 28525998 )
2017
31
The effect of metformin use on pregnancy rates among polycystic ovary syndrome patients undergoing in vitro fertilization: A retrospective-cohort study. ( 28951677 )
2017
32
The cardiometabolic effect of current management of polycystic ovary syndrome: strategies of prevention and treatment. ( 28944709 )
2017
33
Circulatory microRNA 23a and microRNA 23b and polycystic ovary syndrome (PCOS): the effects of body mass index and sex hormones in an Eastern Han Chinese population. ( 28193283 )
2017
34
Decreased expression of fatty acid amide hydrolase in women with polycystic ovary syndrome. ( 28132572 )
2017
35
Can the source of hyperandrogenism in adolescents with polycystic ovary syndrome predict metabolic phenotype? ( 28649885 )
2017
36
Ghrelin is independently associated with anti-mullerian hormone levels in obese but not non-obese women with polycystic ovary syndrome. ( 28004236 )
2017
37
Dysregulation of the anti-MA1llerian hormone system by steroids in women with polycystic ovary syndrome. ( 28938480 )
2017
38
Overexpression of IL-18 in the Proliferative Phase Endometrium of Patients With Polycystic Ovary Syndrome. ( 27313119 )
2017
39
Effects of metformin treatment on serum levels of C-reactive protein and interleukin-6 in women with polycystic ovary syndrome: a meta-analysis: A PRISMA-compliant article. ( 28953677 )
2017
40
Association between biochemical hyperandrogenism parameters and Ferriman-Gallwey score in patients with polycystic ovary syndrome: A systematic review and meta-regression analysis. ( 28575537 )
2017
41
Promoter methylation of yes-associated protein (YAP1) gene in polycystic ovary syndrome. ( 28079802 )
2017
42
Features of polycystic ovary syndrome (PCOS) in women with functional hypothalamic amenorrhea (FHA) may be reversible with recovery of menstrual function. ( 29073797 )
2017
43
Erratum: Combined letrozole and clomiphene versus letrozole and clomiphene alone in infertile patients with polycystic ovary syndrome [Erratum]. ( 28496306 )
2017
44
Association between fat mass and obesity associated (FTO) gene rs9939609 A/T polymorphism and polycystic ovary syndrome: a systematic review and meta-analysis. ( 28826396 )
2017
45
Pathway and network-based analysis of genome-wide association studies and RT-PCR validation in polycystic ovary syndrome. ( 28949383 )
2017
46
Frequency of nodular goiter and autoimmune thyroid disease and association of these disorders with insulin resistance in polycystic ovary syndrome. ( 28400351 )
2017
47
Risk of Type 2 Diabetes Mellitus following Gestational Diabetes Pregnancy in Women with Polycystic Ovary Syndrome. ( 29423416 )
2017
48
Metabolic profiling reveals reprogramming of lipid metabolic pathways in treatment of polycystic ovary syndrome with 3-iodothyronamine. ( 28082426 )
2017
49
The effects of coenzyme Q10 supplementation on gene expression related to insulin, lipid and inflammation in patients with polycystic ovary syndrome. ( 28949260 )
2017
50
The relationship between thyroid function and metabolic changes in Chinese women with polycystic ovary syndrome. ( 28051891 )
2017

Variations for Polycystic Ovary Syndrome

Expression for Polycystic Ovary Syndrome

Search GEO for disease gene expression data for Polycystic Ovary Syndrome.

Pathways for Polycystic Ovary Syndrome

Pathways related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.57 CYP11A1 CYP17A1 CYP21A2 HSD3B2 INS
2
Show member pathways
12.32 CYP17A1 INS LEP PRL
3 12.28 CYP11A1 CYP17A1 CYP19A1 IGFBP1 INS INSR
4
Show member pathways
12.24 IGF1 INS INSR LEP
5 11.73 IGF1 INS INSR
6 11.71 IGF1 INS LEP
7 11.68 CYP11A1 CYP21A2 HSD3B2
8
Show member pathways
11.58 CYP11A1 CYP17A1 CYP19A1 CYP21A2 HSD11B1 HSD3B2
9
Show member pathways
11.39 CYP17A1 CYP19A1 HSD3B2
10 11.31 FST IGF1 INS
11 11.26 INS INSR LEP PRL
12
Show member pathways
11.25 CYP11A1 CYP17A1 CYP19A1 CYP21A2 HSD11B1 HSD3B2
13 11.18 IGF1 INS INSR
14 11.09 CYP19A1 FSHR GDF9
15 11.02 CYP11A1 HSD11B1 PRL
16 10.98 CYP11A1 CYP17A1 CYP19A1 FSHR GDF9 HSD3B2
17 10.83 GNRH1 SHBG
18 10.62 FSHR GNRH1

GO Terms for Polycystic Ovary Syndrome

Cellular components related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.28 FST GDF9 GNRH1 IGF1 IGFBP1 INS
2 endosome lumen GO:0031904 8.96 INS PRL

Biological processes related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 9.95 GDF9 GNRH1 IGF1 INS LEP PRL
2 cellular protein metabolic process GO:0044267 9.9 IGF1 IGFBP1 INS PRL
3 glucose homeostasis GO:0042593 9.82 INS INSR LEP
4 female pregnancy GO:0007565 9.81 GNRH1 LEP PRL
5 steroid metabolic process GO:0008202 9.81 CYP11A1 CYP17A1 CYP21A2 HSD11B1
6 insulin receptor signaling pathway GO:0008286 9.79 IGFBP1 INS INSR
7 glucose metabolic process GO:0006006 9.77 H6PD INS LEP
8 positive regulation of MAPK cascade GO:0043410 9.73 IGF1 INS INSR LEP
9 positive regulation of DNA replication GO:0045740 9.72 IGF1 INS INSR
10 activation of protein kinase B activity GO:0032148 9.7 IGF1 INS INSR
11 positive regulation of mitotic nuclear division GO:0045840 9.67 IGF1 INS INSR
12 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.67 FSHR IGF1 INS LEP
13 uterus development GO:0060065 9.64 CYP19A1 FSHR
14 positive regulation of insulin receptor signaling pathway GO:0046628 9.62 INS LEP
15 male sex determination GO:0030238 9.62 GNRH1 INSR
16 androgen biosynthetic process GO:0006702 9.61 CYP17A1 HSD3B2
17 positive regulation of respiratory burst GO:0060267 9.58 INS INSR
18 neuron projection maintenance GO:1990535 9.58 INS INSR
19 positive regulation of glycolytic process GO:0045821 9.58 IGF1 INS INSR
20 positive regulation of developmental growth GO:0048639 9.57 INSR LEP
21 bone mineralization involved in bone maturation GO:0035630 9.56 IGF1 LEP
22 positive regulation of glucose import GO:0046326 9.56 CAPN10 IGF1 INS INSR
23 mineralocorticoid biosynthetic process GO:0006705 9.54 CYP21A2 HSD3B2
24 positive regulation of glycogen biosynthetic process GO:0045725 9.5 IGF1 INS INSR
25 sterol metabolic process GO:0016125 9.46 CYP11A1 CYP17A1 CYP19A1 CYP21A2
26 steroid biosynthetic process GO:0006694 9.35 CYP11A1 CYP17A1 CYP19A1 CYP21A2 HSD3B2
27 glucocorticoid biosynthetic process GO:0006704 8.92 CYP17A1 CYP21A2 HSD11B1 HSD3B2
28 positive regulation of cell proliferation GO:0008284 10.03 GDF9 IGF1 INS INSR LEP
29 oxidation-reduction process GO:0055114 10 CYP11A1 CYP17A1 CYP19A1 CYP21A2 H6PD HSD11B1

Molecular functions related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.7 CYP11A1 CYP17A1 CYP19A1 CYP21A2 H6PD HSD11B1
2 iron ion binding GO:0005506 9.67 CYP11A1 CYP17A1 CYP19A1 CYP21A2
3 heme binding GO:0020037 9.62 CYP11A1 CYP17A1 CYP19A1 CYP21A2
4 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.56 CYP11A1 CYP17A1 CYP19A1 CYP21A2
5 insulin-like growth factor I binding GO:0031994 9.43 IGFBP1 INSR
6 insulin-like growth factor II binding GO:0031995 9.4 IGFBP1 INSR
7 insulin-like growth factor receptor binding GO:0005159 9.13 IGF1 INS INSR
8 hormone activity GO:0005179 9.02 GNRH1 IGF1 INS LEP PRL

Sources for Polycystic Ovary Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....